Literature DB >> 27111044

Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide.

R R Pol1, N Russell1, E Das-Gupta1, L Watson1, L Rachael1, J Byrne1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27111044     DOI： 10.1038/bmt.2016.99

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  16 in total

1.  Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.

Authors:  R Chopra; J D Eaton; A Grassi; M Potter; B Shaw; C Salat; P Neumeister; G Finazzi; M Iacobelli; K Bowyer; H G Prentice; T Barbui
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

2.  Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Authors:  Kit Man Wong; Eshetu G Atenafu; Dennis Kim; John Kuruvilla; Jeffrey H Lipton; Hans Messner; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-21       Impact factor: 5.742

3.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Authors:  Selim Corbacioglu; Simone Cesaro; Maura Faraci; Dominique Valteau-Couanet; Bernd Gruhn; Attilio Rovelli; Jaap J Boelens; Annette Hewitt; Johanna Schrum; Ansgar S Schulz; Ingo Müller; Jerry Stein; Robert Wynn; Johann Greil; Karl-Walter Sykora; Susanne Matthes-Martin; Monika Führer; Anne O'Meara; Jacek Toporski; Petr Sedlacek; Paul G Schlegel; Karoline Ehlert; Anders Fasth; Jacek Winiarski; Johan Arvidson; Christine Mauz-Körholz; Hulya Ozsahin; Andre Schrauder; Peter Bader; Joseph Massaro; Ralph D'Agostino; Margaret Hoyle; Massimo Iacobelli; Klaus-Michael Debatin; Christina Peters; Giorgio Dini
Journal:  Lancet       Date:  2012-02-23       Impact factor: 79.321

Review 4.  How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation.

Authors:  Enric Carreras
Journal:  Br J Haematol       Date:  2014-11-17       Impact factor: 6.998

Review 5.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

6.  Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

7.  High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.

Authors:  C Schmid; M Schleuning; M Hentrich; G E Markl; A Gerbitz; J Tischer; G Ledderose; D Oruzio; W Hiddemann; H-J Kolb
Journal:  Bone Marrow Transplant       Date:  2008-01-07       Impact factor: 5.483

8.  BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.

Authors:  Fiona L Dignan; Robert F Wynn; Nedim Hadzic; John Karani; Alberto Quaglia; Antonio Pagliuca; Paul Veys; Michael N Potter
Journal:  Br J Haematol       Date:  2013-09-17       Impact factor: 6.998

9.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Nicolaus Kröger; Ernst Holler; Guido Kobbe; Martin Bornhäuser; Rainer Schwerdtfeger; Herrad Baurmann; Arnon Nagler; Wolfgang Bethge; Matthias Stelljes; Lutz Uharek; Hannes Wandt; Andreas Burchert; Paolo Corradini; Jörg Schubert; Martin Kaufmann; Peter Dreger; Gerald G Wulf; Hermann Einsele; Tatjana Zabelina; Hans Michael Kvasnicka; Jürgen Thiele; Ronald Brand; Axel R Zander; Dietger Niederwieser; Theo M de Witte
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

10.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Authors:  Paul G Richardson; Carol Murakami; Zhezhen Jin; Diane Warren; Parisa Momtaz; Deborah Hoppensteadt; Anthony D Elias; Joseph H Antin; Robert Soiffer; Thomas Spitzer; David Avigan; Scott I Bearman; Paul L Martin; Joanne Kurtzberg; James Vredenburgh; Allen R Chen; Sally Arai; Georgia Vogelsang; George B McDonald; Eva C Guinan
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113
View more
  2 in total

Review 1.  Defibrotide in the treatment of hepatic veno-occlusive disease.

Authors:  Alessandro Fulgenzi; Maria Elena Ferrero
Journal:  Hepat Med       Date:  2016-10-31

2.  Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).

Authors:  Paul Richardson; Saurabh Aggarwal; Ozlem Topaloglu; Kathleen F Villa; Selim Corbacioglu
Journal:  Bone Marrow Transplant       Date:  2019-02-25       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.